Merck beats first-quarter expectations on Keytruda, Gardasil strength
(Reuters) -Drugmaker Merck & Co Inc on Thursday posted better-than-expected results for the first quarter on the strength of its blockbuster cancer immunotherapy Keytruda and human papillomavirus (HPV) vaccine Gardasil. Shares of the company rose 1.8% to $114.98 in premarket trading after the drugmaker raised its full-year forecasts for sales and earnings, citing strong global…
